Welcome to our dedicated page for Iterum Therapeutics Plc SEC filings (Ticker: ITRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Iterum Therapeutics’ latest disclosures but buried under technical jargon? Clinical-stage biotech reports are packed with trial statistics, FDA discussions, and cash-runway math that can stretch well past 250 pages. For investors tracking antibiotic innovators, missing a single footnote could mean overlooking a pivotal clinical milestone or dilution warning.
Stock Titan solves that problem. Our AI reads every Iterum Therapeutics quarterly earnings report 10-Q filing, Iterum Therapeutics annual report 10-K simplified, and Iterum Therapeutics 8-K material events explained in real time, then delivers plain-English summaries of R&D spend, Fast Track designations, and trial results. Need to monitor Iterum Therapeutics insider trading Form 4 transactions? Receive alerts on Iterum Therapeutics Form 4 insider transactions real-time so you instantly see when executives buy or sell shares.
Every document type is covered:
- 10-K & 10-Q: cash runway, pipeline updates, risk factors—Iterum Therapeutics SEC filings explained simply
- 8-K: outcome of Phase 3 studies, FDA feedback
- DEF 14A: Iterum Therapeutics proxy statement executive compensation tied to clinical milestones
- Form 4: Iterum Therapeutics executive stock transactions Form 4 for insider sentiment
With our AI-powered summaries, you’ll quickly access Iterum Therapeutics earnings report filing analysis, compare quarter-over-quarter R&D trends, and assess how new data might impact valuation—all without combing through endless pages. Stay informed with comprehensive coverage, real-time updates, and expert context that turns dense biotech filings into actionable insights.
Iterum Therapeutics plc has received a notice from Nasdaq that it no longer meets the Nasdaq Capital Market’s continued listing standards for market value and certain financial criteria. On December 11, 2025, Nasdaq stated that Iterum’s Market Value of Listed Securities had stayed below $35 million for 30 consecutive business days, violating Listing Rule 5550(b)(2), and that the company also fails the alternative shareholder equity and net income requirements.
Iterum has 180 calendar days, until June 9, 2026, to restore its market value to at least $35 million for a minimum of 10 consecutive business days or face potential delisting, with a right to appeal. The company also remains out of compliance with Nasdaq’s $1.00 minimum bid price rule after a prior August 25, 2025 notice and has until February 23, 2026 to achieve a closing bid of at least $1.00 for 10 consecutive business days, with a possible additional 180‑day period if it meets other listing standards. Iterum’s shares continue to trade on Nasdaq for now while it works to regain compliance.
Iterum Therapeutics plc (ITRM) reported an insider share purchase by a director. On 11/18/2025, the director bought 6,000 ordinary shares at a price of $0.3652 per share in an open-market transaction coded "P." Following this trade, the director beneficially owned 241,001 ordinary shares, held as a direct ownership position. No derivative securities transactions were reported in this filing.
Iterum Therapeutics (ITRM) filed its Q3 2025 report highlighting early commercialization and liquidity pressure. The company recorded its first product revenue of $390 thousand from ORLYNVAH™, launched in August 2025, while posting a net loss of $8.98 million for the quarter. Operating expenses rose with commercialization, including $6.49 million in selling, general and administrative costs and $1.26 million in R&D.
Cash and cash equivalents were $11.0 million as of September 30, 2025, and management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing. Net cash used in operating activities was $15.26 million for the nine months. The balance sheet shows a shareholders’ deficit of $7.38 million, a Pfizer promissory note of $21.22 million, and royalty-linked notes of $12.24 million long-term and $0.28 million current. ORLYNVAH™ revenue is modest at launch, reflecting early-stage uptake through EVERSANA’s commercialization platform.
Shares outstanding were 52,787,679 as of November 13, 2025. Results underscore commercialization progress but also the need for capital to support operations and market expansion.
Iterum Therapeutics plc filed a Form 8-K announcing it has furnished a press release with its financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information is being furnished—not deemed “filed” under Section 18 of the Exchange Act—and will not be incorporated by reference into other SEC filings. The filing is administrative in nature and includes the Inline XBRL cover page as Exhibit 104.
Iterum Therapeutics plc filed a prospectus supplement to sell up to $20,000,000 of ordinary shares in an at-the-market program through H.C. Wainwright & Co., not to exceed 21,756,057 ordinary shares. Sales may be made on the Nasdaq Capital Market or by other permitted methods, with Wainwright acting as sales agent.
The program is limited to the company’s authorized but unissued share capacity. Based on 21,756,057 shares currently available for issuance and an assumed price of $0.7377, the company indicates it could sell up to approximately $16,049,443 under the agreement. Iterum will pay a 3.0% sales commission to Wainwright and would receive the net proceeds.
This supplement supersedes the prior ATM supplement, moving the remaining $4,775,345 capacity under that document into this one. Iterum reports aggregate gross proceeds of approximately $36.2 million previously raised under the sales agreement. Ordinary shares outstanding were 48,051,157 as of September 15, 2025. The shares trade on Nasdaq as “ITRM.”
Iterum Therapeutics (ITRM) filed a prospectus supplement to sell ordinary shares from time to time under its existing at‑the‑market program, targeting additional aggregate gross proceeds of up to $20,000,000, not to exceed 21,756,057 shares, through H.C. Wainwright & Co. as sales agent.
The company previously sold approximately $36.2 million of shares under the same Sales Agreement and earlier prospectuses. Iterum also noted it commercially launched ORLYNVAH™ in the U.S. community market in August 2025 and expects modest sales in 2025 during the early commercialization phase.
Michael W. Dunne, a director of Iterum Therapeutics plc (ITRM), filed a Form 4 reporting a transaction on 08/08/2025. The filing shows a reported acquisition of 15,000 ordinary shares at $0.7236. Following the transaction, Mr. Dunne beneficially owned 235,001 shares on a direct basis. The Form 4 bears his signature dated 08/12/2025.
FAQ
What is the current stock price of Iterum Therapeutics Plc (ITRM)?
What is the market cap of Iterum Therapeutics Plc (ITRM)?
